DRC Launches Ebola Vaccine Trial Against Bundibugyo Strain
DRC launched Ervebo vaccine trials to test protection against the Bundibugyo Ebola strain, targeting about 20,000 frontline workers in Ituri and North Kivu over six to twelve months with backing from WHO and MSF. The outbreak has 7,541 confirmed cases and 3,639 deaths, with 70,000 doses allocated for the BRAVO/phase 3 study to assess cross-protection against Bundibugyo.
Health · 5 sources · Sep 21, 2026Read it
The journal
Open the journal →The conversation starts in the journal — be the first to post.
About VSV-EBOV
Recombinant vesicular stomatitis virus–Zaire Ebola virus (rVSV-ZEBOV), also known as Ebola Zaire vaccine live and sold under the brand name Ervebo, is an Ebola vaccine for adults that prevents Ebola caused by the Zaire ebolavirus. When used in ring vaccination, rVSV-ZEBOV has shown a high level of protection. Around half the people given the vaccine have mild to moderate adverse effects that include headache, fatigue, and muscle pain.
Everything about VSV-EBOV →